A Phase 1 interventional study of SPY003-207 and Placebo in Healthy, sponsored by Spyre Therapeutics, Inc.. Active, not recruiting at 2 sites in 2 countries. Open to participants aged 18 Years to 60 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-03-20.
Sponsored by Spyre Therapeutics, Inc. · Phase 1, Interventional, and Basic science
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
This is a Phase 1, randomized, double-blind, placebo-controlled, single dose, first in human safety, tolerability, and pharmacokinetic study of SPY003-207 in healthy participants.
Spyre Therapeutics, Inc. is the lead sponsor of 8 studies on the registry; 3 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants will receive a single dose of SPY003-207 in a dose escalation format
Drug: SPY003-207
Participants will receive a single dose of placebo
Other: Placebo
Participants of Chinese descent will receive a single dose of SPY003-207-101
Drug: SPY003-207
Participants of Chinese descent will receive a single dose of placebo
Other: Placebo
Participants will receive two doses of SPY003-207-101 in a dose escalation format
Drug: SPY003-207
Participants will receive two doses of placebo
Other: Placebo
Experimental
Placebo
Treatment emergent adverse events
Incidence, severity, and causal relationship of TEAEs
Time frame: Up to 63 weeks
Cmax
Maximum concentration after a single dose
Time frame: Up to 63 weeks
Tmax
Time to reach maximum concentration after a single dose
Time frame: Up to 63 weeks
t1/2
Half life after a single dose
Time frame: Up to 63 weeks
AUC
Area under the curve after a single dose
Time frame: Up to 63 weeks
ADA
Incidence of anti-drug antibody after a single dose
Time frame: Up to 63 weeks
Plan to share: No
No publications or documents are linked to this record.
Started Mar 2025 (actual). Primary completion is estimated for Nov 2026, 20 months after the start.
How these figures are worked out, and which studies are left out of them.
This study is active, not recruiting, as verified in Mar 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Spyre Therapeutics, Inc.